Ergomed Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Ergomed wird ein jährliches Gewinn- und Umsatzwachstum von 14.2% bzw. 8.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 13.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 19.3% betragen.

Wichtige Informationen

14.2%

Wachstumsrate der Gewinne

13.7%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum	19.6%
Wachstumsrate der Einnahmen	8.8%
Zukünftige Eigenkapitalrendite	19.3%
Analystenabdeckung	Good
Zuletzt aktualisiert	13 Nov 2023

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

If You Had Bought Ergomed (LON:ERGO) Stock Five Years Ago, You Could Pocket A 643% Gain Today

Feb 22

Has Ergomed plc's (LON:ERGO) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Jan 18

Ergomed plc's (LON:ERGO) Intrinsic Value Is Potentially 20% Below Its Share Price

Dec 13

We Think Ergomed's (LON:ERGO) Statutory Profit Might Understate Its Earnings Potential

Nov 23

Gewinn- und Umsatzwachstumsprognosen

AIM:ERGO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (GBP Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	199	27	29	33	7
12/31/2024	180	23	26	30	7
12/31/2023	161	20	23	26	7
6/30/2023	152	15	17	19	N/A
3/31/2023	149	15	15	17	N/A
12/31/2022	145	15	13	15	N/A
9/30/2022	139	14	14	15	N/A
6/30/2022	132	13	15	16	N/A
3/31/2022	126	13	16	17	N/A
12/31/2021	119	13	18	19	N/A
9/30/2021	110	12	18	19	N/A
6/30/2021	102	12	17	18	N/A
3/31/2021	94	11	17	18	N/A
12/31/2020	86	10	17	18	N/A
9/30/2020	80	8	16	17	N/A
6/30/2020	73	6	16	17	N/A
3/31/2020	71	6	13	14	N/A
12/31/2019	68	6	11	12	N/A
9/30/2019	66	1	7	8	N/A
6/30/2019	64	-3	2	4	N/A
3/31/2019	59	-6	1	3	N/A
12/31/2018	54	-9	1	2	N/A
9/30/2018	54	-8	1	2	N/A
6/30/2018	54	-8	1	3	N/A
3/31/2018	51	-6	0	1	N/A
12/31/2017	48	-5	-1	0	N/A
9/30/2017	42	-2	-2	-1	N/A
6/30/2017	36	0	-4	-2	N/A
3/31/2017	33	0	N/A	-2	N/A
12/31/2016	29	0	N/A	-2	N/A
9/30/2016	31	1	N/A	-2	N/A
6/30/2016	28	1	N/A	-2	N/A
3/31/2016	29	1	N/A	-1	N/A
12/31/2015	30	2	N/A	0	N/A
9/30/2015	29	1	N/A	1	N/A
6/30/2015	28	1	N/A	2	N/A
3/31/2015	24	1	N/A	1	N/A
12/31/2014	21	1	N/A	1	N/A
9/30/2014	19	1	N/A	0	N/A
6/30/2014	16	1	N/A	-1	N/A
3/31/2014	16	1	N/A	0	N/A
12/31/2013	15	2	N/A	1	N/A
12/31/2012	15	0	N/A	1	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ERGODas prognostizierte Gewinnwachstum (14.2% pro Jahr) liegt über der Sparquote (1.5%).

Ertrag vs. Markt: ERGODie Erträge des Unternehmens (14.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt UK (14.6% pro Jahr).

Hohe Wachstumserträge: ERGODie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: ERGODie Einnahmen des Unternehmens (8.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt UK (3.5% pro Jahr).

Hohe Wachstumseinnahmen: ERGODie Einnahmen des Unternehmens (8.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: ERGODie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (19.3%).

Ergomed Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Ergomed plc Provides Earnings Forecast for the Full Year 2023

Consensus EPS estimates increase by 11%

Consensus forecasts updated

Ergomed plc Provides Revenue Guidance for the Year Ended 31 December 2021

Price target increased to UK£13.65

Price target increased to UK£12.70

Recent updates

Ergomed Submits an Application London Stock Exchange in Relation to the Cancellation of the Admission to Trading of its Shares on AIM, Expects to Take Place on 14 November 2023

Permira Advisers Ltd. completed the acquisition of Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others.

Ergomed Confirms Expected Scheme Timetable

Ergomed plc (AIM:ERGO) acquired Panacea Pharma Projects Limited from Stuart Colligon.

Permira Advisers Ltd. entered into a scheme of arrangement to acquire Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others for approximately £700 million.

Ergomed plc to Report Q2, 2023 Results on Sep 26, 2023

Now 20% undervalued after recent price drop

Is It Time To Consider Buying Ergomed plc (LON:ERGO)?

Ergomed plc Provides Earnings Forecast for the Full Year 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ergomed plc, Annual General Meeting, Jun 22, 2023

At UK£9.74, Is Ergomed plc (LON:ERGO) Worth Looking At Closely?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new and inexperienced directors

Ergomed plc to Report Fiscal Year 2022 Results on Mar 21, 2023

High number of new and inexperienced directors

Ergomed plc Announces Board Changes, Effective 3 February 2023

Ergomed plc Announces Executive Changes

Ergomed plc Announces Directorate Changes

Ergomed Announces Two Senior Appointments to its Executive Team

Ergomed Strengthens Executive Management Team

Ergomed Strengthens Executive Management Team

Ergomed plc (LON:ERGO) Shares Could Be 21% Below Their Intrinsic Value Estimate

First half 2022 earnings released: EPS: UK£0.15 (vs UK£0.14 in 1H 2021)

Ergomed plc to Report First Half, 2022 Results on Sep 27, 2022

Investor sentiment improved over the past week

Should You Be Adding Ergomed (LON:ERGO) To Your Watchlist Today?

Why Ergomed plc (LON:ERGO) Could Be Worth Watching

Ergomed plc Appoints Anne Whitaker as Independent Non-Executive Director

Full year 2021 earnings: EPS misses analyst expectations

Ergomed plc, Annual General Meeting, Jun 10, 2022

Consensus EPS estimates increase by 11%

Consensus forecasts updated

Less than half of directors are independent

Now 21% undervalued

Calculating The Fair Value Of Ergomed plc (LON:ERGO)

Full year 2021 earnings: EPS misses analyst expectations

Does Ergomed (LON:ERGO) Deserve A Spot On Your Watchlist?

John Dawson, Cbe Joins the Board of Ergomed plc as Independent Non-Executive Director and Chair of the Audit Committee

Why Ergomed plc (LON:ERGO) Could Be Worth Watching

Ergomed plc to Report Fiscal Year 2021 Results on Mar 29, 2022

Pharmaust Limited Engages Ergomed Clinical Research Ltd to Commence Clinical Trials Testing the Anti-Viral Effects of Monepantel

Ergomed plc (AIM:ERGO) acquired Adamas Consulting Ltd. at an enterprise value of £24.2 million.

Ergomed plc Provides Revenue Guidance for the Year Ended 31 December 2021

Investor sentiment deteriorated over the past week

Calculating The Fair Value Of Ergomed plc (LON:ERGO)

Investor sentiment improved over the past week

I Ran A Stock Scan For Earnings Growth And Ergomed (LON:ERGO) Passed With Ease

First half 2021 earnings released: EPS UK£0.14 (vs UK£0.089 in 1H 2020)

Calculating The Intrinsic Value Of Ergomed plc (LON:ERGO)

Investor sentiment improved over the past week

If You Like EPS Growth Then Check Out Ergomed (LON:ERGO) Before It's Too Late

Getting In Cheap On Ergomed plc (LON:ERGO) Might Be Difficult

Ergomed plc (LON:ERGO) Shares Could Be 31% Above Their Intrinsic Value Estimate

Price target increased to UK£13.65

Non-Executive Director has left the company

Investor sentiment improved over the past week

Do Ergomed's (LON:ERGO) Earnings Warrant Your Attention?

Full year 2020 earnings released

Price target increased to UK£12.70

If You Had Bought Ergomed (LON:ERGO) Stock Five Years Ago, You Could Pocket A 643% Gain Today

New 90-day high: UK£12.45

Ergomed plc to Report Fiscal Year 2020 Results on Mar 23, 2021

Price target raised to UK£11.85

Has Ergomed plc's (LON:ERGO) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

New 90-day high: UK£10.55

Ergomed plc (AIM:ERGO) acquired MedSource Consulting Inc. for $25 million.

Ergomed plc's (LON:ERGO) Intrinsic Value Is Potentially 20% Below Its Share Price

New 90-day high: UK£9.50